Comparative Pharmacology
Head-to-head clinical analysis: SACUBITRIL AND VALSARTAN versus TEVETEN HCT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SACUBITRIL AND VALSARTAN versus TEVETEN HCT.
SACUBITRIL AND VALSARTAN vs TEVETEN HCT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sacubitril inhibits neprilysin, increasing natriuretic peptides; Valsartan blocks angiotensin II type 1 receptor, reducing vasoconstriction and aldosterone release. Combined, they enhance vasodilation, decrease sympathetic activity, and reduce cardiac remodeling.
TEVETEN HCT combines eprosartan mesylate, an angiotensin II receptor antagonist, and hydrochlorothiazide, a thiazide diuretic. Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Initial dose: 24 mg/26 mg (sacubitril 24 mg/valsartan 26 mg) orally twice daily, then double at 2- to 4-week intervals to target maintenance dose of 97 mg/103 mg twice daily.
One tablet orally once daily, containing eprosartan 600 mg and hydrochlorothiazide 12.5 mg or 25 mg, with or without food. Maximum dose: eprosartan 600 mg/hydrochlorothiazide 25 mg per day.
None Documented
None Documented
Sacubitrilat terminal half-life is approximately 11.5 hours; valsartan terminal half-life is approximately 9.9 hours. Twice-daily dosing maintains therapeutic concentrations.
Eprosartan: 5-9 hours; Hydrochlorothiazide: 6-15 hours; allows once-daily dosing.
Sacubitril is converted to sacubitrilat, which is primarily eliminated renally (52–68% as sacubitrilat) and via biliary/fecal routes (37–48% as metabolites). Valsartan is predominantly eliminated via biliary/fecal route (83%) with renal elimination accounting for 13%.
Eprosartan: renal (70% unchanged, 10% as metabolite), biliary/fecal (20%); Hydrochlorothiazide: renal (≥95% unchanged).
Category D/X
Category C
ARB
ARB + Thiazide Diuretic Combination